Priliximab

Anti-CD4 MAb, CEN 000029, MT 412, cMT 412, Centara®

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Van der Lubbe PA, Reiter C, Miltenburg AM, et al. Treatment of rheumatoid arthritis with a chimeric CD4 monoclonal antibody (cM-T412): immunopharmacological aspects and mechanisms of action. Scand J Immunol 1994 Mar; 39: 286–94
Article PubMed Google Scholar
Knox S, Hoppe RT, Maloney D, et al. Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood 1996 Feb 1; 87: 893–9
PubMed CAS Google Scholar
Meiser BM, Reiter C, Reichenspurner H, et al. Chimeric monoclonal CD4 antibody: a novel immunosuppressant for clinical heart transplantation. Transplantation 1994 Aug 27; 58: 419–23
Article PubMed CAS Google Scholar
Stronkhorst A, Radema S, ten Berge I, et al. Phase 1 multipledose pilot study of chimeric monoclonal M-T412 (anti CD4) antibodies in Crohn’s disease. Gastroenterology 1993 Apr; 104 Suppl.: A784
Google Scholar
Moreland LW, Pratt PW, Mayes MD, et al. Double-blind, placebo-controlled multicenter trial using chimeric monoclonal anti-CD4 antibody, cM-T412, in rheumatoid arthritis patients receiving concomitant methotrexate. Arthritis Rheum 1995 Nov; 38: 1581–8
Article PubMed CAS Google Scholar
Tesi RJ, Henry ML, Elkhammas EA, et al. The frequency of rejection episodes after combined kidney-pancreas transplant: the impact on graft survival. Transplantation 1994 Aug 27; 58: 424–30
Article PubMed CAS Google Scholar

Priliximab. Drugs R&D 1, 95–96 (1999). https://doi.org/10.2165/00126839-199901010-00031

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.